The progression for the therapy of liver fibrosis targeting to hepatic stellate cells

Following chronic liver injury of any etiology, there is progressive fibrosis. The identification of activated hepatic stellate cells(HSCs) as the major fibrogenic cell type in the injury liver, as well as the recognition of key cytokines involved in this process, has facilitated the design of promising new antifibrotic therapies. These therapies aimed at inhibiting the accumulation of activated HSCs at the cites of liver injury and preventing the deposition of extracellular matrix. This review describes the current therapeutic approaches for liver fibro-sis, with hepatic stellate cells as a target.